Document is current

Article History

Received: 21 January 2022

Accepted: 9 September 2022

First Online: 24 September 2022

Declarations

:

: The ABNL-MARRO 001 study protocol and associated informed consent documents (ICDs) were approved by the Vanderbilt University Medical Center Institutional Review Board (Nashville, Tennessee, USA; Approval 11/24/2021; IRB #211924). Participating sites of the ABNL-MARRO 001 study will obtain approval of the study protocol and associated informed consent documents (ICDs) from the local institutional review board/independent ethics committee (IRB/IEC). The study is enrolling and registered at as #NCT04061421. The study complies with the Declaration of Helsinki and the principles of Good Clinical Practice guidelines and will be carried out in keeping with all local legal and regulatory requirements. Prospective study participants will be informed orally and in writing of the nature, scope, and possible outcomes of participation in the trial. An IRB/IEC-approved ICD will be signed by each participant before he/she enrolls in the study. No procedures for the study may be initiated prior to obtaining signed informed consent.

: Not applicable.

: Tamara K. Moyo:NoneJason Mendler:NoneRaphaël Itzykson:Research Funding Janssen Novartis, AbbvieHonoraria: Abbvie, Amgen, Astellas, BMS/Celgene, Daiichi-Sankyo, Jazz, Karyopharm, ServierConsulting: Abbvie, Amgen, Novartis, Otsuka Pharma, Jazz Pharmaceuticals, Karyopharm, StemLine.Ashwin Kishtagari:NoneEric Solary:Advisor: Stemline therapeutics.Adam Seegmiller:NoneAaron T. Gerds:Consulting/Advisory: Celgene (Bristol-Myers Squibb), Pfizer, Kartos Therapeutics, CTI Biopharma, Promedior.Research funding: Roche, Celgene (Bristol-Myers Squibb), Incyte, Imago Biosciences.Gregory D. Ayers:NoneAmy E. DeZern:Consulting honoraria from Abbie, Taiho, Novartis.Aziz Nazha:Amazon (own stocks).Speaker Bureau: Incyte Corporation, Novartis.Data monitoring committee: MEI Pharma.Advisory Board / Consulting (pharmaceutical/biotechnology): Karyopharma, Abbvie, Daiichi Sankyo.Peter Valent:COI—study related: no.COI—unrelated to this study: P.V. received honoraria from Celgene/BMS, Novartis, AOP Orphan Pharmaceuticals, Pfizer, and Incyte.Arjan A. van de Loosdrecht:NoneFrancesco Onida:None.Lisa Pleyer:Honoraria from AbbVie, Agios, Bristol Myers Squibb (BMS), Celgene, Inflection Point Biomedical Advisors, and Novartis.Blanca Xicoy Cirici:NoneRaoul Tibes:Employment: AstraZeneca.Klaus Geissler:Speaker and Consultancy Honoraria: Abbvie, Celgene, Novartis.Rami S. Komrokji:Speaker bureau: JAZZ, BMS.Honoraria/consulting: Jazz, BMS, Geron, Abbvie, Acceleron, Novartis.Jing Zhang:NoneUlrich Germing:Speakers Honoraria: Celgene, Jazz, Novartis, Janssen.Institutional Research Support: Celgene, Novartis.David P. Steensma:Employment: Novartis.Daniel H. Wiseman:Research funding: Astex.Speaker/consultancy honoraria: Novartis, StemLine, Takeda, Celgene.Michael Pfeilstoecker:Speaker and Consultancy Honoraria: Abbvie, Astellas, Takeda, Celgene, and Novartis.Chiara Elena:Advisory boards for Novartis, Pfizer, Gilead.Nicholas C.P. Cross:Novartis: consultancy and research support; Incyte: consultancy.Jean-Jacques Kiladjian:Novartis, Celgene, Abbvie, AOP Orphan: advisory boards.Michael Lübbert:Research Support: Janssen, Cheplapharm, TEVA.Travel Support: Janssen.Ruben Mesa:Consultant: Novartis, Sierra Oncology, La Jolla, Samus.Research Support – Incyte, CTI, Celgene, Abbvie, Imago.Guillermo Montelban-Bravo:NoneGuillermo F. Sanz:Honoraria: Celgene.Consulting or Advisory Role: Roche, Novartis, Takeda, Boehringer Ingelheim, Abbvie, Helsinn Healthcare, Amgen, Celgene, Janssen.Uwe Platzbecker:Received honoraria and research funding from Celgene, Janssen, Jazz, Novartis and Amgen.Mrinal M. Patnaik:Advisory board for Kura Oncology and Stem Line therapeutics.Eric Padron:Research funding: Kura Oncology, Incyte Corporation, and BMS, and serves as a consultant for Taiho Oncology and Blueprint Medicines.Valeria Santini:Honoraria: Celgene/Bristol-Myers Squibb, Novartis, Janssen-Cilag.Consulting or Advisory Role: Celgene/Bristol-Myers Squibb, Novartis, Menarini, Takeda, Pfizer, Geron, Gilead Sciences.Research Funding: Celgene.Travel, Accommodations, Expenses: Janssen-Cilag, Celgene.Pierre Fenaux:Research support, as GFM chairperson, from AbbVie, Celgene, Janssen, Novartis.Michael R. Savona:Research funding from ALX Oncology, Astex, Incyte, Takeda and TG Therapuetics; consults or serves on advisory or DSMB for AbbVie, BMS, Forma, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, TG Therapeutics; and has equity in Karyopharm and Ryvu.